RxDoctor Payments Data

Anil George, MD

Internal Medicine · Jacksonville, FLNPI 1679639470

Payments from drug & device makers

$403,575in general payments, 2019–2025

Across 684 payments — averaging $590.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$332K
  • Amgen$60K
  • AstraZeneca$2K
  • Novo Nordisk$993
  • Bayer$816
  • AbbVie$776
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$11,87897%
  • Education$3793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$403,575 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$184,635
Medicare patients
265
Services billed
2,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin146$157,468
OzempicSemaglutide113$131,582
EliquisApixaban124$112,816
FarxigaDapagliflozin Propanediol95$103,724
MounjaroTirzepatide51$61,089
JanuviaSitagliptin Phosphate49$60,652
LinzessLinaclotide66$53,102
XareltoRivaroxaban49$51,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$43,222
EntrestoSacubitril/Valsartan28$42,921
TrulicityDulaglutide14$33,969
GenotropinSomatropin13$26,383
TradjentaLinagliptin23$24,281
VascepaIcosapent Ethyl32$23,827
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$15,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$181$181,749169 claims
PfizerEliquis, Genotropin$602$139,199137 claims
Novo NordiskOzempic, Novolog$993$138,388150 claims
AstraZenecaFarxiga, Brilinta, Symbicort$1,705$122,098127 claims
Lilly USA, LLCMounjaro, Trulicity$612$95,05865 claims
MerckJanuvia, Belsomra$332,488$68,67968 claims
GSKTrelegy Ellipta, Breo Ellipta$719$58,64255 claims
AbbVieLinzess, Lumigan$776$57,16077 claims
Johnson & JohnsonXarelto$232$51,29849 claims
NovartisEntresto$149$42,92128 claims
Sanofi-aventis U.S. LLCLantus$248$3,09219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →